Search
Novo Nordisk acquires Embark Biotech.
As part of the acquisition, Novo Nordisk acquired Embark’s lead metabolic program, and Embark Laboratories and Novo Nordisk also enter into a 3-year research and development collaboration to develop new medications for the treatment of obesity and related complications. The agreed consideration comprises an upfront cash payment of EUR 15m, plus the right to certain milestone-based payments up to EUR 456m.
Novo Nordisk is a global market-leading healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic diseases.
Embark Laboratories is an early-stage biotech company focused on developing novel treatments with clear unmet needs within cardiometabolic and hyperphagic (i.e. food-craving) indications.
Gorrissen Federspiel assisted Novo Nordisk as external counsel on the transaction. The transaction team consisted of Anders Ørjan Jensen, Lasse Myrup, Rikke Vestergaard and Søren Høgh Thomsen.
We congratulate all parties on the transaction.
Read more about the transaction here.